Blood collector Vitalant reported on Thursday a critical shortage of blood as supplies have been significantly impacted by the COVID-19 pandemic.
Since early March, shelter-in-place orders have resulted in a loss of 150,000 uncollected blood donations, while the resumption of surgeries and other medical procedures have caused a 25% increase in the need for blood in the past several weeks.
Calling on donors to alleviate the shortage, Vitalant said that all blood types are critically needed right now, with an especially high need for type O, A-negative and B-negative red blood cells. In addition, platelets are always needed by patients for cancer treatments, surgeries and emergencies. Because of a short shelf life of just five days, the supply of platelets must be continually replenished.
Insilico Medicine signs multi-year research and development collaboration with Servier
MemorialCare hospitals recognised in 2026 Women's Choice Awards
International Isotopes Inc to change name to Radnostix Inc
Delcath publishes Phase 3 FOCUS subgroup data supporting HEPZATO in metastatic uveal melanoma
Corcept announces receipt of FDA Complete Response letter for relacorilant in hypercortisolism
Sensiva Health names new chief operating officer
HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China
SOFIE Biosciences reports first patient dosed Phase 3 clinical trial of [18F]FAPI-74
ABL Bio receives upfront payment and equity investment from Eli Lilly
Harbour BioMed and Yantai Lannacheng Biotechnology form collaboration to advance next-gen RDCs
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer